New England Biolabs, Inc. engages in the discovery and production of enzymes for molecular biology applications. The company offers recombinant and native enzymes for genomic research, proteomics, and drug discovery. It offers restriction endonucleases, polymerases and amplification products, DNA modifying enzymes and cloning products, markers and ladders, competent cells, strains, RNA reagents, epigenetics, glycobiology and protein tools, and buffers; and products for gene expression and cellular analysis. The company offers its products for applications, including cellular imaging and analysis, DNA amplification and polymerase chain reaction, DNA cloning, gene reporter systems, protein expression and purification, protein tools and glycomics, RNA analysis, and sample preparation for sequencing. It offers products through a network of distributors, affiliates, and subsidiaries in Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, the Federal Republic of Germany, Finland, France, Greece, Hong Kong, Iceland, India, the Republic of Ireland, Israel, Italy, Japan, Korea, Luxembourg, Malaysia, Mexico, the Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, Taiwan, Thailand, and the United Kingdom. The company was founded in 1974 and is based in Ipswich, Massachusetts.
